Press Releases Archives - Page 2 of 5

DiaCarta Receives Regulatory COFEPRIS Approval in Mexico & ICMR Approval in India for its FDA EUA Approved QuantiVirus™ SARS-CoV-2 Test

by Claudia Li | Jul 15, 2020 | Press Releases

Press release BlogConferencesPress ReleasesWebinars & VideosPublications Home ❯News & Events❯Press Releases❯ You are here❯ Home❯ Month❯ July❯ DiaCarta Receives Regulatory COFEPRIS Approval in Mexico & ICMR Approval in India for its FDA EUA Approved QuantiVirus™...

DiaCarta SARS-CoV-2 Test Detecting 3 Viral Genes Receives US FDA Emergency Use Authorization & Test Manufacturing Expanded to 500K COVID-19 Tests/Week

by Claudia Li | Apr 13, 2020 | Press Releases

Press release BlogConferencesPress ReleasesWebinars & VideosPublications Home ❯News & Events❯Press Releases❯ You are here❯ Home❯ Author❯ Claudia Li❯ DiaCarta SARS-CoV-2 Test Detecting 3 Viral Genes Receives US FDA Emergency Use Authorization & Test Manufacturing...

DiaCarta Inc. has filed for EUA with the FDA and has received CE mark for its highly sensitive QuantiVirus™ SARS-CoV-2 Test Kit

by Claudia Li | Mar 25, 2020 | Press Releases

Press release BlogConferencesPress ReleasesWebinars & VideosPublications Home ❯News & Events❯Press Releases❯ You are here❯ Home❯ Author❯ Claudia Li❯ DiaCarta Inc. has filed for EUA with the FDA and has received CE mark for its highly sensitive QuantiVirus™ SARS-CoV-2...

CIO Bulletin Announces DiaCarta Inc. As One of the 30 Fastest Growing Companies of 2018

by DiaCarta Inc. | Jan 17, 2019 | Press Releases

Press release BlogConferencesPress ReleasesWebinars & VideosPublications Home ❯News & Events❯Press Releases❯ You are here❯ Home❯ Author❯ DiaCarta Inc.❯ CIO Bulletin Announces DiaCarta Inc. As One of the 30 Fastest Growing Companies of 2018 FollowFollowFollow RICHMOND,...

DiaCarta Inc. Launches Ultra-Sensitive TaqMan-Based qPCR Assays for Cancer Gene Mutation Detection

by DiaCarta Inc. | Oct 29, 2018 | Press Releases

Press release BlogConferencesPress ReleasesWebinars & VideosPublications Home ❯News & Events❯Press Releases❯ You are here❯ Home❯ Author❯ DiaCarta Inc.❯ DiaCarta Inc. Launches Ultra-Sensitive TaqMan-Based qPCR Assays for Cancer Gene Mutation Detection...

DiaCarta, Inc., Awarded $2 Million NCI Contract to Pursue Regulatory Approval of Innovative Cancer Radiation Response Blood Test

by DiaCarta Inc. | Oct 15, 2018 | Press Releases

Press release BlogConferencesPress ReleasesWebinars & VideosPublications Home ❯News & Events❯Press Releases❯ You are here❯ Home❯ Author❯ DiaCarta Inc.❯ DiaCarta, Inc., Awarded $2 Million NCI Contract to Pursue Regulatory Approval of Innovative Cancer Radiation...

« Older Entries

Next Entries »

Register and Learn!

Join our mailing list to receive the latest news and updates from our team.

DiaCarta Receives Regulatory COFEPRIS Approval in Mexico & ICMR Approval in India for its FDA EUA Approved QuantiVirus™ SARS-CoV-2 Test

DiaCarta SARS-CoV-2 Test Detecting 3 Viral Genes Receives US FDA Emergency Use Authorization & Test Manufacturing Expanded to 500K COVID-19 Tests/Week

DiaCarta Inc. has filed for EUA with the FDA and has received CE mark for its highly sensitive QuantiVirus™ SARS-CoV-2 Test Kit

CIO Bulletin Announces DiaCarta Inc. As One of the 30 Fastest Growing Companies of 2018

DiaCarta Inc. Launches Ultra-Sensitive TaqMan-Based qPCR Assays for Cancer Gene Mutation Detection

DiaCarta, Inc., Awarded $2 Million NCI Contract to Pursue Regulatory Approval of Innovative Cancer Radiation Response Blood Test

Recent Posts

Recent Comments

Archives

Categories

Meta

Register and Learn!

You have Successfully Subscribed!